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CD4+ T cells producing interleukin-10 (IL-10) and
interferon-g (IFN-g) are reported in chronic infections.
However, the signals that direct the development of
IL-10-producing T helper 1 (Th1) cells are undefined.
We showed that development of IL-10-producing
Th1 cells required high T cell receptor (TCR) ligation,
sustained ERK1 and ERK2 MAP kinases phosphory-
lation, and IL-12-induced STAT4 transcription factor
activation. Repeated TCR triggering led to enhanced
IL-10 production by Th1 cells, and continued IL-12
action and high-dose TCR signaling were required
for the development and maintenance of IL-10-
producing Th1 cells. Although Th1, Th2, and Th17
cells require the activation of distinct STATs for their
differentiation, activation of ERK1 and ERK2 was a
common requirement for production of IL-10 by all
Th cell subsets. IL-10 expression also correlated
with c-maf expression. Despite having distinct func-
tions in protection against pathogens, all Th cells
share the important task of controlling overexuberant
immune responses by means of IL-10 production.
INTRODUCTION
Interleukin-10 (IL-10) is a cytokine with broad anti-inflammatory
properties that inhibits macrophage and dendritic cell (DC) func-
tion (Moore et al., 2001). IL-10 limits the immune and inflamma-
tory responses to pathogens and gut flora and prevents damage
to the host (Moore et al., 2001; O’Garra and Vieira, 2004), but
when dysregulated may result in chronic infection (Brooks
et al., 2006; Ejrnaes et al., 2006; Moore et al., 2001). IL-10 is ex-
pressed by T helper 2 (Th2) cells, B cells, DCs, andmacrophages
(Moore et al., 2001), and also by Th1 cells (Anderson et al., 2007;
Assenmacher et al., 1994; Del Prete et al., 1993; Gerosa et al.,1996; Jankovic et al., 2007; Pohl-Koppe et al., 1998) and (re-
viewed in O’Garra and Vieira, 2007; Trinchieri, 2007), certain
regulatory (Treg) T cells (Moore et al., 2001; O’Garra and Vieira,
2004; Roncarolo et al., 2006), and Th17 cells (Awasthi et al.,
2007; Fitzgerald et al., 2007; McGeachy et al., 2007; Stumhofer
et al., 2007).
In vitro human CD4+ and CD8+ T cell clones, or mouse CD4+
T cells that produce both interferon-g (IFN-g) and IL-10, can be
differentiated by T cell receptor (TCR)-stimulation in the presence
of IL-12 (Chang et al., 2007; Gerosa et al., 1996; Jeannin et al.,
1996;Meyaard et al., 1996;Windhagenet al., 1996). Furthermore,
Th1 cell clones coproducing IFN-g and IL-10 have been isolated
from bronchoalveolar lavage (BAL) of active pulmonary tubercu-
losis (TB) patients (Gerosa et al., 1999). IL-10 production by Th1
cells was also reported in animals infected with Toxoplasma
gondii (Jankovic et al., 2002;Shawet al., 2006) orwithLeishmania
major (Anderson et al., 2007) and shown to be required for regu-
lation of the immune response in these infections (Anderson et al.,
2007; Jankovic et al., 2007). The relative amounts of IL-10 and
IFN-g produced by Th1 cells may influence the balance between
clearance and persistent infectionwith certain pathogens (Moore
et al., 2001; Trinchieri, 2007), thus determining whether chronic
infection or immunopathology ensues.
Th1, Th2, and Th17 cell responses differentiate along distinct
signaling pathways (Glimcher and Murphy, 2000; Ivanov et al.,
2007; Stockinger and Veldhoen, 2007). Th1 cell development
requires signal transducer and activator of transcription
(STAT)1 activation, induced by type I IFN or IFN-g, the transcrip-
tion factor T-box 21 (T-bet), and IL-12-induced STAT4 signaling,
which can couple with IL-18-induced IRAK and NF-kB transcrip-
tion factors to drive the high amounts of IFN-g required to eradi-
cate intracellular pathogens (Glimcher and Murphy, 2000). Th2
cell development, with expression of IL-4, IL-5, and IL-13,
requires IL-4, STAT6, and the transcription factor GATA binding
protein (GATA)-3 (Glimcher andMurphy, 2000). Thedevelopment
of Th17 cells requires IL-6, TGF-b, and the STAT3-dependent
expression of the transcription factor RORgt (Ivanov et al.,
2007; Stockinger and Veldhoen, 2007).Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc. 209
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Mechanisms for IL-10 Induction in Th CellsTh1 and Th2 cell responses can also be induced by varying the
dose of antigen presented to the naive T cell by the antigen-pre-
senting cell (APC).Whereas high doses of antigen,with sustained
TCR signaling and extracellular-signal regulated (ERK) mitogen-
activated protein kinase (MAPK) phosphorylation, result in Th1
cells producing IFN-g via an IL-12-independent mechanism,
low doses of antigen, with transient ERK1 and ERK2 activation,
favor Th2 responses and IL-4 secretion (Constant et al., 1995;
Hosken et al., 1995; Jorritsma et al., 2003; Yamane et al., 2005).
Because Th1 and Th2 cells cross regulate each other’s devel-
opment and function and can suppress Th17 cell responses, and
all differentiate along distinct signaling pathways (Glimcher and
Murphy, 2000; Stockinger and Veldhoen, 2007), IL-10 produced
by all these Th cells may thus act as a feedback regulator to
control the pathology associated with an overexuberant, albeit
efficacious, inflammatory response. Whether IL-10 production
by these different Th cell subsets is induced by independent
and/or common mechanisms is unknown.
Here, we showed that in vitro differentiation of IL-10-producing
Th1 cells from naive CD4+ T cells required IL-12-induced STAT4
signaling, strong TCR activation (high antigen dose), and sus-
tained ERK1 and ERK2 phosphorylation. Furthermore, we
showed that activation of ERK1 and ERK2 is a requirement for
production of IL-10 by Th1, Th2, and Th17 cell subsets. This
common but highly regulated pathway for IL-10 induction and
maintenance ensures its function as a feedback loop to control
damage to the host and also allows a protective response to
ensue as opposed to chronic infection.
RESULTS
IL-12 and High Doses of Antigen Induce
the Development of Th1 Cells Producing IL-10
To study the differentiation of Th1 cells coproducing IFN-g and
IL-10, we cultured purified TCR-transgenic DO11.10 naive
CD4+ T cells with purified DCs as APCs and increasing doses
of ovalbumin peptide 323-339 (OVA). Culture with high doses
of antigen for 7 days gave rise to Th1 cells expressing IFN-g
upon restimulation (Constant et al., 1995; Hosken et al., 1995),
but not IL-10 (Figure S1A available online). Culture with low
antigen doses under the same conditions led to the differentia-
tion of Th2 cells, which expressed both IL-4 and IL-10 upon
restimulation (Figure S1A). Culture of naive CD4+ T cells in an
APC-free system by stimulation with anti-CD3 and anti-CD28
antibodies in the presence of IL-12 resulted in IFN-g-producing
Th1 cells, a proportion of which coproduced IL-10, as did Th2
cells resulting from culture in IL-4 (Figure S1B).
To investigate whether the lack of IL-10 produced by Th1 cells
resulted from inhibition of IL-10 production by DCs and high
antigen dose or alternatively required IL-12, we cultured naive
CD4+ T cells with increasing doses of antigen presented by DC
in the presence of IL-12. At low doses of antigen, IL-12 abro-
gated the development of Th2 cells and induced IFN-g expres-
sion but only low levels of IL-10 expression, suggesting that
IL-12 per se was not sufficient to induce significant IL-10 produc-
tion in Th1 cells (Figure 1A). Strikingly, as the antigen dose was
increased, Th1 populations driven with IL-12 now contained
higher numbers of IL-10-producing cells (Figure 1A) and
produced more IL-10 protein upon restimulation (Figures 1A210 Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc.and 1B). Thus, the development of Th1 cells producing IL-10
required both IL-12 and high doses of antigen. Th1 cells differen-
tiated to produce large amounts of IL-10 and IFN-g and lost
their capacity to produce IL-2 (Figure 1B). Because the presence
of IL-12 reduced the proliferation of CD4+ T cells at both high
and low antigen doses (Table S1), and only the former showed
IL-10 production, the development of high IL-10-producing
cells is most likely not related to limited IL-2. Naive CD4+ T cells
A
B
Figure 1. IL-12 Enhances IL-10 Production at High Antigen Dose
Only
Naive CD4+ T cells from DO11.10 TCR transgenic animals were isolated and
differentiated for 1 week with splenic DCs in medium containing increasing
doses of OVA in the absence (medium) or presence of IL-12, as indicated.
On day 7, cells were restimulated for 4 hr with plate-bound anti-CD3 and
soluble anti-CD28 and BrefeldinA and (A) stained at the single-cell level for
IL-10, IFN-g, and IL-4, or (B) stimulated similarly for 48 hr in the absence of
BrefeldinA, and the culture supernatants analyzed by ELISA. Data are repre-
sentative of six experiments performed; error bars in (B) refer to the standard
deviation of three independent cultures.
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Mechanisms for IL-10 Induction in Th Cellsfrom DO11.10/recombination-activating gene 1 (Rag1)-deficient
animals, cultured with high doses of antigen in the presence of
IL-12, also resulted in IL-10 expression by Th1 cells, showing
that this expression was not dependent on the presence of
effector or memory T cells or Treg cells (Figure S2). Although it
has been suggested that TGF-b can induce IL-10 in CD4+
T cells (Kitani et al., 2003; Schiott et al., 2000), we found that in
developing Th1 and Th2 cells this was not the case (data not
shown). In fact, neutralization of TGF-b led to increased IL-10
production by both T cell subsets (Figure S3). Thus, the develop-
ment of IL-10-producing Th1 cells only depended on the pres-
ence of IL-12 together with high antigen dose and not on other
soluble factors such as IL-2 or TGF-b or on the presence of other
T cell types.
IL-10 Production by Th1 Cells Is Dependent on STAT4
but Not on STAT6, IFN-g, or IL-4 Signaling
To further elucidate the mechanisms required for the develop-
ment of Th1 cells producing IL-10, we investigated the role of
STAT4, one of the signaling pathways activated by IL-12 (Murphy




Figure 2. IL-10 Production by Th1 Cells
Requires IL-12-Induced STAT4 Activation
CD4+ T cells from DO11.10 animals on a (A, B, and
C) WT, Stat4/, or Stat6/ background, (D)
Ifng/ background, or (E and F) Il4/ back-
ground were isolated and differentiated as in
Figure 1. As shown in (B), Th2-driven cells were
differentiated for 1 week in medium containing
IL-4 (10 ng/ml) and anti-IL-12 (10 mg/ml) plus
1 mM OVA; or (C and F) 0.05 mM OVA alone (low-
antigen-dose-driven Th2 cells). On day 7, cells
were restimulated and IL-10, IFN-g, and IL-4
production were detected by ICS or by immuno-
assay as in Figure 1. Represented is one of three
experiments performed. Detection of cytokines
by ELISA in the supernatants of cultures restimu-
lated for 48 hr (data not shown) confirmed the
results observed for ICS in (A) and (B). Error bars
refer to the standard deviation of replicate values
of three independent cultures.
(Ouyang et al., 1998) were cultured in
the presence of IL-12 and OVA. Again,
IL-10-producing Th1 cells were differenti-
ated at the high antigen dose in the
presence of IL-12 in DO11.10 T cells (Fig-
ure 2A). In contrast, in the absence of
STAT4, the percentage of cells express-
ing IFN-g was dramatically diminished
as expected and resulted in an increase
in the percentage of cells expressing
IL-4, but not IL-10 (Figure 2A), suggesting
that STAT4 contributes to IL-10 expres-
sion by Th1 cells.
Because IL-10 expression is associ-
ated with an IL-4-induced Th2 cell
phenotype, we investigated whether the
differentiation of the IL-10-producing
Th1 cells depended on signaling through the IL-4 receptor via
STAT6 activation (Glimcher and Murphy, 2000; Murphy et al.,
2000). The absence of STAT6 did not impair the differentiation
of IL-10-producing Th1 cells in the presence of IL-12 and OVA
(Figure 2A). In fact, a higher percentage of STAT6-deficient cells
compared with WT cells produced both IL-10 and IFN-g
(Figure 2A), which may be the result of the loss of Th2 cell control
over a Th1 cell response. As expected, lack of STAT6 abrogated
both IL-4 and IL-10 production by T cells developed with IL-4 or
with low antigen dose (Figures 2B and 2C). However, in the
absence of STAT4 signaling, IL-10 and IL-4 production by Th2
cells was if anything increased (Figures 2B and 2C). Thus, in
contrast to what was observed under Th1 conditions, IL-10
expression by Th2 cells depended on STAT6, but not on
STAT4, signaling (Figures 2B and 2C).
To investigate whether the inability of STAT4-deficient T cells
to produce IL-10 might be due to the absence of IFN-g, as sug-
gested before (Shaw et al., 2006), we differentiated DO11.10 or
DO11.10 IFN-g-deficient naive CD4+ T cells in the presence of
IL-12 and increasing doses of OVA. The secretion of IL-10 as
induced by high antigen dose, and IL-12 was not affected byImmunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc. 211
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Mechanisms for IL-10 Induction in Th Cellsan absence of IFN-g (Figure 2D), showing that the expression
of IL-10 by Th1 cells is independent of IFN-g. In the absence of
IFN-g, we observed an increase in the secreted IL-4 as expected
(data not shown).
We also tested for any potential role of IL-4 in the development
of Th1 cells producing IL-10 by culturing DO11.10 or DO11.10 IL-
4-deficient naive CD4+ T cells with IL-12 and increasing doses of
antigen. As observed in the absence of STAT6 (Figure 2A), IL-4
deficiency had no effect on the development of Th1 cells
producing IL-10 (Figure 2E), but compromised the development
of Th2 cells producing IL-10 (Figure 2F). Thus, our data sug-
gested that IL-10 production by Th1 or Th2 cells was dependent
on the specific signaling pathways required for their differentia-
tion, given that STAT4 is required for the induction of IL-10
production by Th1 cells and STAT6 for Th2 cells.
High Antigen Doses and STAT4 Are Required for the
In Vivo Generation of IL-10-Producing Th1 Cells
To address the mechanisms regulating IL-10 production by Th1
cells in vivo, we transferred DO11.10 cells into BALB/c recipient
mice and immunized the recipients with very high doses of OVA-
protein with or without added lipopolysacharide (LPS). T cells
were recovered from the inguinal lymph nodes 3 days after
priming and restimulated in vitro with OVA peptide for 48 hr.
This in vivo immunization induced IL-10 and IFN-g production,
and the amount of IL-10 production was enhanced by addition
of LPS in the immunization (Figure 3A) and with higher doses
of OVA (3 mM versus 1 mM, data not shown). To test the role of
STAT4 and STAT6 signaling in the in vivo development of
IL-10-producing Th1 cells, we transferred STAT4- or STAT6-
deficient or WT DO11.10 cells into recipient BALB/c mice and
immunized with OVA-protein plus LPS as before. In vivo expres-
sion of both IL-10 and IFN-g was markedly reduced but not
completely abrogated in the absence of STAT4 signaling (Fig-
ures 3B and 3C), suggesting the existence of compensatory
mechanisms that were absent in the in vitro system. Signaling
through STAT6 had no effect on IL-10 production by Th1 cells
as shown by intracellular cytokine staining (ICS) and by immuno-
assay in STAT6-deficient T cells (Figures 3B and 3C).
IL-10 Production Is Maintained by High TCR Signal
Strength and IL-12
We next investigated whether repeated strong TCR activation is
a compensatory signal for IL-12-induced STAT4 signaling in the
induction of IL-10 in Th1 cells. For this, CD4+ T cells were differ-
entiated for 2 consecutive weeks with high antigen doses in the
presence or absence of IL-12 throughout (Figures 4A–4D). High
antigen dose and IL-12 cooperated to induce maximal IL-10
production (Figures 4A and 4B), given that this combination
resulted in the highest numbers of IL-10-producing Th1 cells.
Repeated high antigen dose stimulation in the absence of exog-
enously added IL-12 resulted in the production of IL-10 by Th1
cells, suggesting that repeated strong TCR triggering may
overcome the need for IL-12 for IL-10 induction (Figures 4C
and 4D). However, IL-10 induction under these conditions was
abrogated when IL-12p40-deficient DCs were used as APCs
(Figure 4E). Thus, IL-12 is essential during both primary and
secondary antigenic stimulation for production of IL-10 by Th1
cells.212 Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc.To determine the requirements for stability of the IL-10-
producing Th1 cells, we differentiated CD4+ T cells for 1 week
with high antigen doses with or without IL-12 (Figures 4A and
4C), washed them, and then restimulated them for an additional
week with a low antigen dose, in the absence or presence of
IL-12 (Figure 4F). Th1 cells induced in the first week to produce
IL-10 by culture with high antigen doses and IL-12 lost their
ability to express IL-10 when recultured with low doses of
OVA, which could be compensated for, to some extent, by addi-
tion of IL-12 to the secondary cultures (Figure 4F), again suggest-
ing that antigen dose and IL-12 signals cooperate for the induc-
tion of IL-10. Finally, DO11.10 CD4+ cells that were exposed to
low doses of antigen and IL-12 during the primary differentiation
phase produced high amounts of IFN-g but little IL-10, but they
could be induced to produce IL-10 when both high antigen dose
and IL-12 were present during the recall phase (Figure S4). Thus,
high antigen dose and IL-12 are required for sustaining the




Figure 3. In Vivo Generation of IL-10-Producing Th1 Cells Requires
High Antigen Dose, Innate Immune Signals and STAT4
(A) Spleen cell suspensions from DO11.10 animals were injected into BALB/c
recipients. Cells were isolated from the inguinal lymph nodes of mice injected
with PBS, OVA protein (5 mg) plus or minus LPS (5 mg) and restimulated in vitro
with OVA for 48 hr. IL-10 and IFN-g production was analyzed by ELISA.
Represented is the mean ± SD of groups of three animals each. Spleen cell
suspensions from DO11.10 WT (ten animals), Stat4/ (nine animals), or
Stat6/ (ten animals) were transferred into BALB/c recipients, which were
then injected with OVA protein and LPS (5 mg and 5 mg, respectively). Cells
recovered as above were restimulated in vitro, for 24–48 hr with the last 6 hr
in the presence (for ICS, B) or absence (for ELISA, C) of BrefeldinA. IL-10
and IFN-g expression was detected by ICS and represented within the CD4+
KJ1-26+ T cells population.
(B) We obtained the plots represented by merging the plots from each mouse
within one group. Two independent experiments confirmed the result showed
and the mean percentage of IL-10/IFN-g producers ± SD was 3.95 ± 1.15 and
2.25 ± 0.68; 4.29 ± 1.36 and 7.11 ± 1.86; and 3.82 ± 0.96 and 10.19 ± 2.25 for
DO11.10 WT, Stat4/, and Stat6/, respectively.
(C) Error bars refer to the standard deviation of replicate values on two inde-
pendent experiments.
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Mechanisms for IL-10 Induction in Th CellsIL-10 Production by Th1 Cells Requires ERK1
and ERK2 Activation
Our data showed that the maintenance of IL-10 induction in Th1
cells required stimulation with high antigen dose, which to some
extent could be compensated for by the addition of IL-12.
Signaling through the TCR with high doses of antigen induced
stronger ERK1 and ERK2 activation than that induced by low
antigen dose, not only in naive CD4+ T cells (data not shown)
as previously demonstrated (Jorritsma et al., 2003) but also in
CD4+ T cells restimulated with the same high and low antigen
doses (Figure 5A). Although the apparent peak and amount of
ERK1 and ERK2 activation varied slightly between experiments,
a consistent finding was that high antigen dose differentiated
Th1 cells always showed enhanced and prolonged ERK1 and
ERK2 activation in the presence of IL-12, regardless of whether
they were restimulated with high or low antigen dose (Figure 5B).
We then investigated whether ERK1 and ERK2 activation was
required for the induction of IL-10 in Th1 cells by using U0126
(Figure 5C), a compound that blocks downstream ERK activa-
tion. To ensure that only T cell signaling was being affected by
U0126, we used an APC-free system in which the T cells were
differentiated in the presence of increasing doses of anti-CD3
and a constant amount of IL-12. As in the APC-driven cultures,
stronger TCR stimulation together with IL-12 led to higher





E Figure 4. High Antigen Dose and IL-12 Are
Required for Maximal Production of IL-10
by Th1 Cells
CD4+ T cells from DO11.10 TCR transgenic
animals were cultured for 1 week with a high
(0.7 mM) dose of OVA and DC in the (A and B) pres-
ence or (C) absence of IL-12 and subsequently
washed, counted, and recultured with a high
(0.7 mM; B, D, and E) or low (0.01 mM; F) dose of
OVA and DC in the absence or presence of IL-12
as indicated. CD4+ T cells from DO11.10 TCR
transgenic animals were cultured with a high
(0.7 mM) dose of OVA and WT or Il12b/ DCs in
the absence of added IL-12 for 2 weeks (E). At the
end of the first (A, C, and E) and the second week
(B, D, E, and F), cells were restimulated with anti-
CD3 and anti-CD28, and IFN-g and IL-10 cytokine
expression were detected by ICS. Represented is
one of three experiments performed.
week of culture (Figure 5C). Addition of
U0126 to the cultures abrogated the
production of IL-10 at all doses of anti-
CD3 (Figure 5C). Because U0126 inhibits
the MEK5-catalyzed activation of ERK5,
as well as the MEK1- and MEK2-cata-
lyzed activation of ERK1 and ERK2 (Bain
et al., 2007; Mody et al., 2001), we also
used the more specific, structurally
unrelated MEK1 and MEK2 inhibitor
PD184352 at concentrations in which it
inhibits MEK1 and MEK2 but not MEK5
(Bain et al., 2007; Mody et al., 2001).
PD184352 caused a similar inhibition of
IL-10 production by Th1 cells in a dose-dependent fashion
(Figure 5D and Figure S5A). Upon addition of inhibitors to
other signaling pathways, including a p38 MAPK inhibitor,
SB203580, or the GSK3b inhibitor, CT99021 (Bain et al., 2007),
no effect on IL-10 production was observed (Figure S5B). Our
data thus suggested that IL-10 production by Th1 cells in
response to high antigen dose and IL-12 requires ERK1 and
ERK2 signaling, but not the activation of the p38 or the GSK3b
pathways.
IL-10 Production by Th2 and Th17 Cells Also Requires
ERK1 and ERK2 Activation
To address whether IL-10 production by Th2 and Th17 cells was
also dependent on ERK1 and ERK2 activation, we differentiated
these cells with anti-CD3 and anti-CD28 in the absence of APCs
(Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al.,
2006), in the presence or absence of the MEK inhibitor
(PD184352). We showed that ERK1 and ERK2 activation is
a common pathway required for induction of IL-10 in different
Th cell subsets because IL-10 production by both Th2 and
Th17 cells was markedly inhibited in the presence of the MEK
inhibitor (PD184352) (Figure 5D and Figure S5B). In contrast,
inhibitors of p38 MAPK or of GSK-3b activation did not affect
the expression of IL-10 by these subsets (Figure S5B). Activation
of the ERK1 and ERK2 signaling pathway is therefore a commonImmunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc. 213
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B
C D
Figure 5. IL-10 Production by Th1, Th2,
and Th17 Cells Requires ERK1 and ERK2
Activation
CD4+ T cells from DO11.10 TCR transgenic
animals were cultured with a high (0.7 mM) or low
(0.01 mM) dose of OVA and DC in the absence or
presence of IL-12. On day 3, cells were harvested,
rested for 5 hr in low (1%) serum medium, and re-
stimulated with high (0.7 mM) or low (0.01 mM)
antigen dose, in the (A and B) absence or in the
(B) presence of IL-12, for the indicated time points.
Cellular lysates were prepared, proteins were
separated by SDS-PAGE, and phospho(p)- or total
(t)-ERK1 and ERK2 were detected by immuno-
blotting. Actin was included as a loading control
(A and B). CD4+ T cells from BALB/c animals
were isolated and cultured for 7 days in the pres-
ence of increasing doses of plate-bound anti-
CD3, soluble anti-CD28, and IL-12 (3 ng/ml), in
the absence (control, with DMSO) or presence of
U0126 (2.5 mM) (MEK Inhibitor). As shown in (C),
on day 7, cells were restimulated as above and
the expression of IL-10 and IFN-g was detected
by ICS. Cytokine production in the supernatants
of 48 hr restimulated cultures was analyzed by
ELISA and confirmed the ICS results (data not
shown). As shown in (D), CD4+ T cells from
BALB/c animals were isolated and cultured for
5 days in the presence of plate-bound anti-CD3,
soluble anti-CD28 and one of the following combi-
nations: IL-12 (3 ng/ml) plus anti-IL-4 (20 mg/ml),
for Th1; IL-4 (10 ng/ml) plus anti-IL-12 (10 mg/ml),
for Th2; or IL-6 (50 ng/ml), TGF-b (1 ng/ml) and
IL-1 (10 ng/ml), for Th17, all in the absence
(control, with DMSO) or presence of PD184352
MEK Inhibitor, as in (C). On day 5, cells were
restimulated with PdBU and ionomycin, and the
expression of IL-10, IFN-g, IL-4, and IL-17 was
detected by ICS. Represented is one of three
(A, B, C, and F) or one of four (D and E) experiments
performed.requirement for the induction of IL-10 production by Th1, Th2,
and Th17 cells.
c-maf Expression Correlates with IL-10 Production
in Th1, Th2, and Th17 Cells
To investigate further the downstream factors involved in regu-
lating IL-10 production, we differentiated DO11.10 CD4+
T cells with increasing doses of OVA, in the presence or absence
of IL-12, and quantified the expression of cytokines and tran-
scription factors by real-time RT-PCR. Low-dose antigen re-
sulted in transcription of Il4 and this was abrogated by both
high antigen doses and IL-12 (Figure 6A). A low amount of
transcription of Ifngwas induced by IL-12 when cells were differ-
entiated with low antigen dose, but this effect of IL-12 wasmark-
edly upregulated with increasing doses of antigen (Figure 6A). A
low amount of Il10 transcription was observed at low doses of
antigen accompanying Il4 expression (Th2 cell response), and
this was abrogated by increased doses of antigen as was Il4
expression (Figure 6A). At low doses of antigen, IL-12 had little
effect to increase IL-10 mRNA expression (Figure 6A) in keeping
with the protein data (Figure 1A). However, IL-12 induced a high214 Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc.amount of Il10 transcription as well as Ifng expression with
increased antigen doses (Figure 6A), again in keeping with the
protein data (Figure 1A).
CD4+ T cells differentiated with increasing doses of antigen did
not express high amounts of Tbx-21 (T-bet) mRNA, unless they
were cocultured with IL-12 (Figure 6B). In contrast, high amounts
of GATA-3 mRNA expression were only observed under Th2 cell
differentiation conditions (low-dose antigen) (Figure 6B), and this
expression was markedly downregulated by both increasing
antigen dose and coculture in IL-12 (Figure 6B). Differentiation
of T cells under low antigen dose led to expression of c-maf, in
keeping with the Th2 cell profile (Ho et al., 1996), which was
almost completely abrogated by increasing doses of antigen
(Figure 6B). Interestingly, IL-12 sustained the high expression
of c-Maf mRNA even at the highest antigen dose (Figure 6B).
Moreover, IL-12 maintenance of c-maf expression required
STAT4 activation (data not shown).
In Th17 cells that expressed IL-17a as well as IL-10 mRNA
(Figure 6C), T-bet and GATA-3 mRNA were undetectable (data
not shown), whereas that of ROR-gt was high (Figure 6C) (Ivanov
et al., 2007). Th17 cells also expressed high amounts of c-maf
Immunity
Mechanisms for IL-10 Induction in Th Cells(Figure 6C), confirming a recent report (Bauquet et al., 2009).
c-Maf is therefore expressed in all IL-10-expressing T cell popu-
lations tested (Figures 6B and 6C) andmay not be just a Th2 cell-
specific transcription factor as originally thought (Ho et al., 1996).
We showed also that like Il10 expression, c-maf expression was
inhibited in Th1 and Th17 cells in the presence of the MEK1 and
MEK2 inhibitor (PD184352), whereas T-bet and RORgt expres-
sion was hardly affected (Figure 6D).
DISCUSSION
IL-10 expression by cells of the innate and adaptive immune
systems reflects the importance of this cytokine in the tight regu-
lation of the immune response, to minimize pathology during
infection. IL-10 expression by Th1 cells has been reported to




Figure 6. c-maf Is Expressed in IL-10-
Producing Th1, Th2, and Th17 Cells
CD4+ T cells from DO11.10 TCR transgenic
animals were differentiated for 1 week in medium
containing increasing doses of OVA plus DC in
the absence (Med) or presence of IL-12, as indi-
cated. On day 7, cells were (A) restimulated for
cytokine expression or (B) not restimulated for
transcription factor expression as in Figure 1.
CD4+ T cells from C57Bl/6 animals were isolated
and cultured for 5 days in the presence of plate-
bound anti-CD3 (50 ng/ml), soluble anti-CD28 (50
ng/ml), IL-6 (50 ng/ml), TGF-b (1 ng/ml), and IL-1
(10 ng/ml); Th17 cells were restimulated on day 5
(for cytokine expression) or not (for transcription
factor expression) as in Figure 5C. Th1 and Th17
cells were cultured as in Figure, all in the absence
(; Control), with DMSO, or presence (+) of the
PD184352 MEK inhibitor. Transcription factor
expression is shown in (D). Similar results were ob-
tained from three (A, B, and C) or two experiments
(D, with two doses of inhibitor or control). Cytokine
and transcription factor expression were analyzed
from RNA isolated from all populations by RT real-
time PCR.
mosis. However, in many situations,
IL-10 is not produced by Th1 cells in
response to antigenic stimulation. Our
goal was to address themolecular signals
that determine whether Th1 cells develop
to produce IL-10 (Trinchieri, 2007). Here,
we showed that Th1 cells required high-
antigen-dose-induced ERK1 and ERK2
phosphorylation and IL-12-induced
STAT-4 activation to produce IL-10. Our
findings that ERK1 and ERK2 activation
was a common pathway required for the
production of IL-10 by Th1, Th2, and
Th17 cell subsets, which differentiate
along distinct pathways, such that IL-10
provides a highly regulated feedback
loop to avoid the extremes of excessive
inflammation or chronic infections and also allow a protective
response to diverse pathogens.
In certain viral or parasitic infections (Anderson et al., 2007;
Brooks et al., 2006; Ejrnaes et al., 2006), high amounts of stimu-
lation may lead to the chronic nonhealing infection shown to be
regulated by IL-10. During the course of infection, after initial
triggering with antigen, T cells migrate to the tissue encountering
high doses of antigen and factors produced by the innate
immune response. Under these conditions, we speculate that
Th1 cells will be induced to express high amounts of IL-10, in
keeping with reports that IL-10-producing Th1 cells were found
in CD4+ clones isolated from BAL but not blood of TB patients
(Gerosa et al., 1999). Similarly, the immune response to a clinical
isolate of L. major, which produces heavily infected nonhealing
lesions, was found to be regulated by IL-10 derived from Foxp3
Th1 cells that coproduce IL-10 and IFN-g (Anderson et al., 2007),Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc. 215
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also to be regulated by Foxp3 Th1 cells (Jankovic et al.,
2007). It is likely that IL-10 production by Th1 cells is evoked
under conditions of high inflammation and antigenic stimulation,
whereas regulatory CD4+ T cells producing IL-10 may operate to
regulate the immune response under conditions in which the
pathogen is clinically controlled, such as in infectionwith L.major
(Friedlin strain) (Belkaid et al., 2002; Suffia et al., 2006). We now
also reported that CD4+ T cells cultured with high antigen dose
and IL-12 differentiate into canonical Th1 effector cells, which,
in addition to expressing large amounts of IFN-g and IL-10,
lose their IL-2 expression as described before in certain chronic
infection models (Sallusto et al., 2004). Our demonstration that
loss of IL-2 is accompanied by production of IL-10 offers poten-
tial additional mechanisms whereby effector T cell responses
may be dampened during chronic disease.
Using an in vivo transfer model of DO11.10 TCR transgenic
cells (Castro et al., 2000), we showed that IL-10-producing Th1
cells were differentiated in the presence of high doses of OVA
protein and LPS. We showed here that this induction of IL-10
in Th1 cells in vivo was markedly, but not totally, reduced in
STAT4-deficient T cells as observed during T. gondii infection
(Jankovic et al., 2002). A high antigenic activation during T. gondii
infection or high antigen doses delivered in the presence of LPS,
as seen in our system, may compensate for an absolute require-
ment for IL-12 in the induction of IL-10 by Th1 cells.
In our in vitro system, repeated stimulation of Th1 cells with
high antigen doses allowed the development of Th1 cells
producing IL-10 in an IL-12-dependentmanner. IL-10 production
by Th1 cells induced by high antigen dose and IL-12 was inde-
pendent of IFN-g, in keeping with previous findings (Jankovic
et al., 2002). However, a role for IFN-g in mediating IL-10 reacti-
vation by Th1 cells during secondary infection with T. gondii
has been suggested (Shaw et al., 2006). We have found that
CD4+ T cells exposed to a high dose of antigen do not express
IL-10 upon restimulation, but can be induced to produce IL-10
upon re-exposure to a high dose of antigen in the recall phase
in the absence of added IL-12. However, this is dependent on
the induction of IL-12 by antigen-presenting DCs. The combina-
tion of both high antigen dose and IL-12 resulted in the highest
levels of IL-10 production and correlated with the high levels of
ERK1 and ERK2 activation. The increased expression of IFN-g
observed during the secondary phase will induce increased
IL-12 production by DCs and suggests that repeated high-level
TCR activation feeds back to upregulate IL-12 production by
DC. It is thus likely that in T. gondii infection in vivo (Shaw et al.,
2006), the requirement for IFN-g to induce IL-10, was for feed-
back upregulation of IL-12 by DCs, which in turn induced IL-10
in the Th1 cells.
Although IL-10 may be differentially regulated in Th1 and Th2
cells as has been reported (Chang et al., 2007; Wang et al.,
2005), some studies suggest the existence of common path-
ways, but the molecular basis for these is as yet unclear. Costi-
mulatory OX-40 signals have been shown to negatively regulate
IL-10 production (Ito et al., 2005) both in Th1 and Th2 cells,
whereas ICOS signaling has been suggested to induce IL-10
(Ito et al., 2007; Witsch et al., 2002) in both Th1 and Th2 cells.
However, in some cases, ICOS signaling also regulates IL-4
production and Th2 responses (Greenwald et al., 2005). We216 Immunity 31, 209–219, August 21, 2009 ª2009 Elsevier Inc.now provide a common mechanism of ERK1 and ERK2 activa-
tion for the regulation of IL-10 production in Th1, Th2, and
Th17 cells, although each subset differentiates along a distinct
and subset-specific transcriptional pathway. This reinforces
the fact that IL-10 is not a Th cell-subset-specific cytokine, but
instead is produced in a tightly regulated fashion during each
differentiation pathway. Of note, a role for ERK1 and ERK2
activation in the induction of IL-10 production has already been
described for macrophages and DC (Agrawal et al., 2006;
Hacker et al., 1999).
Differential transcriptional regulation of IL-10 in Th1 and Th2
cells has been suggested (Chang et al., 2007; Wang et al.,
2005), and extensive histone acetylation of the IL-10 gene is
detectable in fully polarized Th2 cells, but not Th1 cells (Chang
etal., 2007).Weprovideevidence that IL-10 isproduced incanon-
ical Th1 cells and that its expression correlates with the expres-
sion of T-bet and the highest IFN-g production, in keeping with
our observations that high-dose antigen stimulation and IL-12
signaling are required for IL-10 and IFN-g expression. It has also
been shown that maintenance of IL-10 expression is conditional
on IL-12 or IL-4 unless the IL-10 gene is imprinted by GATA-3
(Chang et al., 2007), which can remodel the IL-10 locus, thus
explaining the highest amounts of IL-10 produced by Th2 cells
(Chang et al., 2007; Shoemaker et al., 2006). We show here that
high antigen dose and IL-12 drastically downregulate Gata-3
expression, suggesting that additional factors are in place to
induce IL-10 expression inTh1cells, albeit transiently. Expression
of c-maf was greatly diminished by high antigen doses in T cells
and yet was unexpectedly maintained by IL-12 and present in
Th17 cells. That c-maf expression is common to IL-10-producing
Th1, Th2, andTh17cells and, like IL-10, is dependentonERKacti-
vation in Th1 and Th17 cells for its expression is of interest
because c-Maf has been shown to be an essential transcription
factor for IL-10 expression in macrophages (Cao et al., 2005).
In summary, we show that although Th1, Th2, and Th17 CD4+
T cell subsets differentiate along distinct signaling and transcrip-
tional pathways, they can all be induced to make IL-10. ERK1
and ERK2 activation is required for IL-10 production by all these
Th cell subsets. With regard to the expression of IL-10 by Th1
cells, our data provide a mechanism for how IL-10 expression
is induced and then amplified and regulated by the levels of
antigen and IL-12 encountered in the environment. This provides
a mechanism whereby a Th1 cell responds to extrinsic signals,
reflecting increased inflammation in the tissue, to tightly regulate
the production of IL-10 so as to allow a protective response to
eradicate a pathogen with minimal damage to the host and
also prevent chronic infection. Moreover, our findings have
important implications for the regulation of IL-10 production
during an inflammatory Th1 response in infection and may be
of relevance for the design of vaccines and for strategies in
immunotherapy in infectious diseases.
EXPERIMENTAL PROCEDURES
Mice, Cytokines, Antibodies, and Other Reagents
BALB/c DO11.10 mice transgenic for OVA-specific TCR WT or crossed back
with Rag1-, IL-4-, IFN-g-, STAT4-, and STAT6-deficient mice were used as
a source of antigen-specific T cells (Murphy et al., 1990; Ouyang et al., 1998;
Shoemaker et al., 2006) and were bred and maintained under SPF conditions
at the NIMR, London, Home Office, UK, Animals (Scientific Procedures) Act
Immunity
Mechanisms for IL-10 Induction in Th Cells1986 or at the Washington University School of Medicine. Female mice were
used at 8–12 weeks old, and animal protocols were approved according to
the Animals (Scientific Procedures) Act 1986, Home Office, UK. Reagents,
including antibodies for T cell and DC preparation, purification and culture,
media, cytokines, and cytokine mAbs have been described (Hosken et al.,
1995; Shoemaker et al., 2006; Veldhoen et al., 2009; Veldhoen et al., 2006).
LPS (S. minnesota) was from Alexis, chicken ovalbumin protein (OVA protein)
was from from Sigma-Aldrich, and ovalbumin peptide323-339 (OVA) (endo-
toxin-free) was from Biosynthesis. U0126 was from BioMol International.
PD184352 (MEK inhibitors), SB203580 (p38 inhibitor), and CT99021 (GSK3b
inhibitor)werekindgifts fromP.CohenandN.Shpiro,University ofDundee,UK.
Isolation of CD4+ TCells and of Splenic DC andCell Culture for TCell
Phenotype Differentiation
T cells were sorted for CD4+CD62Lhi, CD4+CD62LhiCD25, or
CD4+CD44loCD25 to >98% on a Moflo cytometer (Cytomation) as before
(Shoemaker et al., 2006; Veldhoen et al., 2009). In most cases, experiments
were reproduced with each type of purified CD4+ T cell population with similar
results obtained. Splenic DCs were prepared as described (Hosken et al.,
1995), and sort purified CD11c+ cells were added to the T cell culture. Purified
DO11.10 CD4+ T cells (13 105 cells/ml) were cultured as before (Hosken et al.,
1995), in a total volume of 1 ml cRPMI medium in a 48-well plate, with splenic
DCs (2 3 104 cells/ml), and varying amounts of OVA and of IL-12. APC-inde-
pendent differentiation of naive CD4+ T cells into Th1 and Th2 cells used stim-
ulation with anti-CD3 and anti-CD28 and appropriate cytokine conditions, and
control Th1 and Th2 cells were cultured as described before (Hosken et al.,
1995; Shoemaker et al., 2006). Culture conditions for Th17 cells were as
described before (Veldhoen et al., 2006). Importantly, Th1 and Th2 cells could
be differentiated in cRPMI or IMDM (Hosken et al., 1995; Shoemaker et al.,
2006; Veldhoen et al., 2006), but Th17 cells were only differentiated optimally
in IMDM (Veldhoen et al., 2009). When indicated, U0126 or PD184352 (MEK
inhibitors), SB203580 (p38 inhibitor), CT99021 (GSK3b inhibitor), or a similar
amount of DMSO were present in the culture. More details of specific culture
conditions are provided in Figures S6 and S7.
Cytokine Detection by ICS and ELISA
At day 5 or 7, cells were restimulated with immobilized anti-CD3 (2 mg/ml) and
anti-CD28 (2 mg/ml) (4 hr with BrefeldinA [10 mg/ml] in the last 2 hr) or with PdBU
and Ionomycin (5 hr with BrefeldinA [1 mg/ml]). After ICS FACS, data were
collected on a FACSCalibur (Becton Dickinson) and analyzed with FlowJo
(Tree Star). For ELISA, cells were similarly restimulated for 48 hr and superna-
tant was collected and analyzed for IL-4, IL-10, and IFN-g as described before
(Shoemaker et al., 2006).
In Vivo Studies
BALB/c mice were injected intravenously (i.v.) with a red blood cell-depleted
single-cell spleen suspension (2.5 3 107 cells) (Castro et al., 2000) from
DO11.10 WT or STAT-deficient mice. After 48 hr, they were injected subcuta-
neouslywith PBSorwithOVAprotein (5mg) plus LPS (5 mg). The inguinal lymph
nodes were removed 48 hr later. A single-cell suspension (1 3 106 cells) was
restimulated for 24 or 48 hr with 1 mM or 3 mM of OVA and with BrefeldinA for
the last 6 hr. Half of the supernatant was removed before the addition of Brefel-
dinA for use in an ELISA assay. The cells were fixed and stained as before.
Those positive for KJ1-26-Bio and for CD4-PerCP were gated, and IFN-g
and IL-10 staining was examined for this population and analyzed as before.
Real-Time Quantitative RT-PCR
Cells were harvested and restimulated in the presence of immobilized anti-
CD3 (2 mg/ml) plus anti-CD28 (2 mg/ml) for 3 hr or immediately lysed. RNA
was extracted and reverse-transcribed and cDNA was analyzed for the
expression of cytokines and transcription factors by real-time PCR assay as
before (Shoemaker et al., 2006). Target genemRNA expression was quantified
either with SYBR Green (Applied Biosystems) or with Master Mix (Applied
Biosystems) and normalized to ubiquitin or HPRT mRNA levels, respectively.
Immunoblotting
Differentiated CD4+ T cells were rested for 5 hr in 1% FCS-containing medium
and restimulated as described for specific experiments. Cell lysates wereprepared, equal amounts of protein were separated by SDS-PAGE, and phos-
phorylated or total ERK and actin were detected as described before (Beinke
et al., 2004).
SUPPLEMENTAL DATA
Supplemental Data include one table, five figures, and two experimental
flowcharts and can be found with this article online at http://www.cell.com/
immunity/supplemental/S1074-7613(09)00317-3.
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